Excision BioTherapeutics Announces Oral Presentation at the 5th Genome Editing Therapeutics Summit

SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a biotechnology company developing CRISPR-based therapies to cure serious viral infectious diseases, today announced that Dr. Ryo Takeuchi, Senior Director, Genome Editing, will deliver an oral presentation at the 5^th Genome Editing Therapeutics Summit (formerly CRISPR 2.0), which is taking place from December 3-5, 2024, in Boston, MA. Dr. Takeuchi will also be chairing a session at the conference entitled, Developing Robust Nonclinical Safety Packages.

About Excision BioTherapeutics, Inc.
Excision BioTherapeutics develops CRISPR-based therapeutics designed to cure viral infectious diseases. The Company is pioneering treatments for herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV), and HIV that target and inactivate the viral DNA. Leveraging the Company’s multiplexed gene editing approach, the Excision pipeline builds upon positive safety and tolerability data from a Phase 1/2 trial evaluating a first-generation therapy, EBT-101, in patients with HIV. Excision’s foundational technologies were developed by Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at UC Berkeley. For more information, please visit www.excision.bio.

Contact:
John Fraunces
LifeSci Advisors
917-355-2395
jfraunces@lifesciadvisors.com